EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM
Overview
The EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM (EFAI AASCTA) is a radiological computer-assisted triage and notification software designed to aid in the rapid identification of acute aortic syndrome (AAS). Utilizing advanced deep learning techniques, the system automatically analyzes chest or chest-abdomen Computed Tomography Angiography (CTA) images.
Upon detecting features suggestive of Aortic Dissection (AD) or Aortic Intramural Hematoma (IMH), the system promptly alerts PACS/RIS workstations. This functionality is intended to assist hospital networks and appropriately trained medical specialists in workflow triage, enabling earlier review of high-risk studies than in standard clinical workflows. The system provides critical decision support through priority reading and alerts. It is important to note that the results are not intended for stand-alone clinical decision-making and do not rule out AAS or preclude clinical assessment of CTA cases.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Radiological computer-assisted triage and notification software
- Utilizes deep learning algorithms for image analysis
- Automatically analyzes chest or chest-abdomen CTA images
- Detects features suggestive of Aortic Dissection (AD) or Aortic Intramural Hematoma (IMH)
- Sends alerts to PACS/RIS workstations for prioritized review
- Provides critical decision support with alerts and notifications
- Aids in early recognition of high-risk acute clinical scenarios
- Seamless integration with existing CT, X-ray, and PACS systems
- Demonstrates high sensitivity and specificity in image detection
- Validated with multi-center, multi-family data
Use Cases
- Facilitating early recognition of high-risk acute aortic syndrome cases in emergency settings
- Optimizing workflow triage for radiologists and medical specialists reviewing CTA scans
- Assisting in the timely diagnosis of Aortic Dissection (AD)
- Supporting the identification of Aortic Intramural Hematoma (IMH)
- Enhancing patient safety through faster identification of critical conditions
- Improving clinical outcomes by enabling earlier intervention for acute aortic syndrome
What Physicians Need to Know
Utilize the EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM to prioritize and rapidly identify suspected cases of aortic dissection and intramural hematoma from CTA scans. This AI-powered tool can significantly accelerate the diagnostic workflow and aid in urgent treatment planning for acute aortic syndrome. Remember that the device is intended to assist in workflow triage and notification, and its results should be integrated with comprehensive clinical evaluation and other diagnostic modalities for definitive clinical decision-making.
The EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM is designed to integrate seamlessly into existing clinical workflows. It alerts PACS/RIS workstations upon identifying suspected pathologies, facilitating efficient communication and data flow within hospital networks. Everfortune.AI's products generally aim for integration with existing PACS systems in hospitals.
Details
| Category | Cardiology AI, Radiology & Imaging AI, Triage & ER/ICU AI |
| Pricing | Contact for pricing |
| Deployment | On-premise (local network, specialized server) |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated The EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM (EFAI AASCTA) received U.S. FDA clearance (K240291) on April 8, 2024. It is a radiological computer-aided triage and notification software indicated for use in the analysis of chest or chest-abdomen CTA in adults aged 22 and older, assisting in flagging suspected positive cases of aortic dissection (AD) or aortic intramural hematoma (IMH) pathology. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Emergency Medicine, Radiology |
What the Web Says
The EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM (EFAI AASCTA) is an AI-powered radiological computer-aided triage and notification software. It is designed to analyze chest or chest-abdomen CTA scans in adults aged 22 and older to identify suspected cases of aortic dissection (AD) or aortic intramural hematoma (IMH). The system aims to assist hospital networks and medical specialists in workflow prioritization by flagging and communicating these suspected positive cases to a PACS/workstation, allowing for earlier review by a radiologist.
Overall: PositiveStrengths
- Aids in workflow triage and prioritization of CTA scans for acute aortic syndrome.
- Uses an artificial intelligence algorithm to identify suspected findings of aortic dissection or intramural hematoma.
- Provides passive notifications to PACS/workstations, integrating with existing systems.
- Allows radiologists to review suspected cases earlier than in standard workflows.
- FDA-authorized for image analysis/processing for cardiovascular using CT/CTA.
- Clinical validation study conducted with a blinded, multisite approach.
Limitations
- Not intended to direct attention to specific portions or anomalies of an image.
- Results are not intended for stand-alone clinical decision-making.
- Does not have a typical user interface for image interaction or manipulation.
- Does not create reports directly; output is case-level for prioritization.
- Poor image capture can lead to poor annotations and measurements.
- Does not exempt users from clinical review and appropriate decision-making.
Based on reviews from: Innolitics, American College of Radiology, accessdata.fda.gov, Radiology AI Tools Directory
Last updated: 2026-07-19
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM
Videos
Product demos, reviews, and walkthroughs for EFAI CARDIOSUITE CTA ACUTE AORTIC SYNDROME ASSESSMENT SYSTEM.
MICCAI Industrial Talk: AI-based Rapid and Accurate Warning of Acute Aortic Syndrome...Oct 14, 2025
